Brokers lift AstraZeneca price targets after strong Q3 results and restructuring plan
AstraZeneca posted third‑quarter 2026 earnings per share of $2.79 and revenue of $16.21 billion, beating expectations. The results prompted three broker houses to raise their price targets – Citi to £189, RBC Capital to GBP152.50 (15,250p) and UBS to 16,000p. The company also announced a restructuring programme that will cost up to $2 billion in one‑off items but is expected to generate $1.5 billion of annualised pre‑tax savings.
Why it matters
Analysts note that the new targets imply a potential upside of roughly 9% to 35% from the current share price of 13,960p. The restructuring savings are slated for reinvestment in the pipeline, supporting future growth.
Key facts
- 1RBC Capital raised its price target to GBP152.50 from GBP145.00. investing.com
- 2AstraZeneca reported Q3 2026 earnings per share of $2.79. investing.com
- 3AstraZeneca reported Q3 2026 revenue of $16.21 billion. investing.com
- 4The restructuring programme is expected to deliver $1.5 billion of annualised pre‑tax savings. investing.com
- 5Citi raised its price target to £189 from £186. finance.yahoo.com
- 6UBS raised its price target to 16,000p from 15,200p. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.